GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » PE Ratio

Asensus Surgical (Asensus Surgical) PE Ratio : At Loss (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-27), Asensus Surgical's share price is $0.249. Asensus Surgical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31. Therefore, Asensus Surgical's PE Ratio for today is At Loss.

Asensus Surgical's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31.

As of today (2024-04-27), Asensus Surgical's share price is $0.249. Asensus Surgical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31. Therefore, Asensus Surgical's PE Ratio without NRI ratio for today is At Loss.

Asensus Surgical's EPS without NRI for the three months ended in Dec. 2023 was $-0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31.

During the past 3 years, the average EPS without NRI Growth Rate was 26.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 46.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 35.70% per year.

During the past 13 years, Asensus Surgical's highest 3-Year average EPS without NRI Growth Rate was 66.40% per year. The lowest was -254.70% per year. And the median was 15.20% per year.

Asensus Surgical's EPS (Basic) for the three months ended in Dec. 2023 was $-0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31.

Back to Basics: PE Ratio


Asensus Surgical PE Ratio Historical Data

The historical data trend for Asensus Surgical's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical PE Ratio Chart

Asensus Surgical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Asensus Surgical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Asensus Surgical's PE Ratio

For the Medical Devices subindustry, Asensus Surgical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asensus Surgical's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's PE Ratio falls into.



Asensus Surgical PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Asensus Surgical's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.249/-0.310
=-0.8(At Loss)

Asensus Surgical's Share Price of today is $0.249.
Asensus Surgical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Asensus Surgical  (AMEX:ASXC) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Asensus Surgical PE Ratio Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Asensus Surgical (Asensus Surgical) Business Description

Traded in Other Exchanges
Address
1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Executives
Starling William N Jr director 2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi director C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert director 343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J. officer: Chief Technology Officer 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze officer: EVP, Chief Financial Officer C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh officer: Interim CFO 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery officer: EVP and CFO C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith officer: Chief Commercial Officer 7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope director, officer: President and CEO C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a 10 percent owner VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Asensus Surgical (Asensus Surgical) Headlines